Table 1. Drug susceptibility of Leishmania donovani clinical isolates following Miltefosine treatment in cases of Visceral Leishmaniasis and Post kala-azar dermal Leishmaniasis.
| WHO code1 | Research code2 | Patient age/sex | Clinical response to treatment | MIL | PMM |
| IC50±SD (µM) | IC50±SD (µM) | ||||
| MHOM/IN/2010/BHU782/0 | V782/0 | 18/M | Cure | 0.95±0.06 | 5.34+1.12 |
| MHOM/IN/2010/BHU869/0 | V869/0 | 10/F | Cure | 1.05±0.08 | 8.97±0.25 |
| MHOM/IN/2010/BHU994/0 | V994/0 | 60/M | Cure | 1.96±0.50 | 9.07±0.15 |
| MHOM/IN/2010/BHU828/0 | V828/0 | 10/M | Cure | 1.98±0.66 | 5.06±0.37 |
| MHOM/IN/2010/BHU902/0 | V902/0 | 7/M | Cure | 2.30±0.36 | 10.70±1.12 |
| MHOM/IN/2009/BHU815/0 | V815/0 | 12/F | Cure | 2.91±0.24 | 7.25±0.55 |
| MHOM/IN/2010/BHU796/1 | V796/1 | NA | Cure | 1.02±0.17 | 5.55±0.89 |
| MHOM/IN/2010/BHU1121/1 | V1121/1 | 12/M | Cure | 1.14±0.11 | 6.05±0.65 |
| MHOM/IN/2010/BHU807/1 | V807/1 | 12/F | Cure | 1.26±0.15 | 9.08±0.65 |
| MHOM/IN/2010/BHU869/1 | V869/1 | 10/F | Cure | 1.32±0.26 | 3.91±0.03 |
| MHOM/IN/2010/BHU1042/1 | V1042/1 | 6/M | Cure | 1.42±0.06 | 4.23±0.76 |
| MHOM/IN/2009/BHU815/1 | V815/1 | 12/F | Cure | 2.27±0.49 | 5.88±0.64 |
| MHOM/IN/2009/BHU741/1 | V741/1 | NA | Cure | 2.35±0.40 | 6.07±1.02 |
| MHOM/IN/2009/BHU800/1 | V800/1 | 35/M | Cure | 2.48±0.04 | 9.80±0.61 |
| MHOM/IN/2010/BHU902/1 | V902/1 | 7/M | Cure | 3.37±0.38 | 9.28±0.40 |
| MHOM/IN/2010/BHU1093/1 | V1093/1 | 20/M | Cure | 3.57±0.35 | 3.41±0.29 |
| MHOM/IN/2009/BHU994/1 | V994/1 | 60/M | Cure | 3.72±0.52 | 5.10±0.65 |
| MHOM/IN/2010/BHU1080/1 | V1080/1 | 12/M | Cure | 4.95±0.28 | 5.80±0.84 |
| MHOM/IN/2010/BHU814/1 | V814/1 | NA | Cure | 5.20±0.80 | 9.20±0.75 |
| MHOM/IN/2010/BHU1113/7 | V1113/7 | 35/M | Relapse | 2.67±0.51 | 7.02±0.86 |
| MHOM/IN/2010/BHU872/6 | V872/6 | 18/M | Relapse | 4.84±0.39 | 10.70±1.02 |
| MHOM/IN/2009/BHU1062/4 | V1062/4 | 7/F | Relapse | 6.66±0.62 | 7.64+0.76 |
| MHOM/IN/1998/NIPP44/0 | P44/0 | 18/M | Cure* | 7.37±0.07 | 5.01±0.38 |
| MHOM/IN/2011/NIPP232/0 | P232/0 | 42/M | Cure | 7.99±0.15 | 8.46±0.77 |
| MHOM/IN/1998/NIPP48/0 | P48/0 | 15/M | Cure* | 8.88±0.18 | 5.80±0.85 |
| MHOM/IN/1998/NIPP49/0 | P49/0 | 23/M | Cure* | 9.23±0.22 | 5.10±0.37 |
| MHOM/IN/2001/NIPP93/0 | P93/0 | 25/M | Cure* | 9.69±0.52 | 6.21±0.37 |
| MHOM/IN/2010/NIPP195/12 | P195/12 | 21/M | Relapse | 13.26±0.89 | 8.62±1.82 |
| MHOM/IN/2010/NIPP214/18 | P214/18 | 35/M | Relapse | 16.70±0.65 | 4.92±0.34 |
| MHOM/IN/2011/NIPP214/32 | P214/32 | 36/M | Relapse | 18.45±0.79 | 5.34±0.75 |
WHO code: country and year of isolation and the respective strain code, the number following the isolate ID indicates the number of months elapsed after start of MIL treatment.
Research code: Parasites cultured from VL patients were labeled V- and from PKDL patients P-, respectively. The number following the isolate ID indicates the number of months elapsed after start of MIL treatment (e.g. V902/1 means one month passed from first MIL treatment). Parasites isolated from patients' prior start of MIL treatment were labeled as XXX/0 and one month following first treatment was labeled XXX/1. These patients cleared from VL symptoms after respective duration of MIL treatment and were interpreted as clinical cure, although residual parasites could be cultured from splenic aspirates (marked XXX/1). In the period of 1 year follow up, cases of relapse were observed in three VL patients that had shown an initial clinical cure, the isolates obtained were designated as XXX/month in which relapse occurred.
Cure*- Patients treated with SAG (1000 mg intra muscularly), daily for four months.